Association of extent of local tumor invasion and survival in patients with malignant primary osseous spinal neoplasms from the surveillance, epidemiology, and end results (SEER) database.

BACKGROUND Malignant osseous spinal neoplasms are aggressive tumors associated with poor outcomes despite aggressive multidisciplinary measures. It remains unknown whether increased local tumor invasion at time of treatment predicts worse survival. The surveillance, epidemiology, and end results (SEER) registry was reviewed to determine whether extent of local tumor invasion at presentation was independently associated with overall survival. METHODS The SEER registry (1973-2003) was queried to identify cases of histologically confirmed primary spinal chordoma, chondrosarcoma, osteosarcoma, or Ewing sarcoma. Extent of local invasion was defined at time of care by histology, radiology, or intraoperative assessment and classified as confined (tumor within periosteum), local invasion (extension to surrounding tissues), or distal metastasis. The association of extent of local tumor invasion with overall survival was assessed by Cox analysis. RESULTS One thousand eight hundred ninety-two patients were identified (414 chordoma, 579 chondrosarcoma, 430 osteosarcoma, 469 Ewing sarcoma). Overall median survival was histology specific (osteosarcoma, 11 months; Ewing sarcoma, 26 months; chondrosarcoma, 37 months; chordoma, 50 months) and correlated with extent of local tissue invasion or metastasis at presentation. Presence of metastasis was associated with marked decrease in survival (P < 0.001) for all tumor types. For patients with isolated spine tumors, neoplasms confined within the periosteum were associated with improved overall survival independent of age, radiotherapy, or surgical resection for chordoma (hazard ratio [HR], 0.50; P = 0.08), chondrosarcoma (HR, 0.62; P = 0.03), and osteosarcoma (HR, 0.68; P = 0.05), but not Ewing sarcoma (HR, 0.62; P = 0.27). CONCLUSIONS The preoperative radiographic recognition of local tissue invasion may identify patients with a more aggressive tumor and help guide the level of aggressiveness in subsequent treatment strategies.

[1]  E. Transfeldt,et al.  Lumbosacral chordoma. Prognostic factors and treatment. , 1999, Spine.

[2]  Kiyoshi Saito,et al.  Long-term control of clival chordoma with initial aggressive surgical resection and gamma knife radiosurgery for recurrence , 2009, Acta Neurochirurgica.

[3]  R. Berk,et al.  Chondrosarcoma of the spine: 1954 to 1997. , 1999, Journal of neurosurgery.

[4]  S. Cannon,et al.  Sacral Chordoma: Can Local Recurrence After Sacrectomy Be Predicted? , 2008, Clinical orthopaedics and related research.

[5]  Ziya L Gokaslan,et al.  Long-Term Clinical Outcomes Following En Bloc Resections for Sacral Chordomas and Chondrosarcomas: A Series of Twenty Consecutive Patients , 2009, Spine.

[6]  A. Bencivenga,et al.  An epidemiological study of osteogenic sarcoma in Kenya , 1985, International Orthopaedics.

[7]  M Beth McCarville,et al.  Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma , 2008, Cancer.

[8]  P. Picci,et al.  Chondrosarcoma of the mobile spine: report on 22 cases. , 2000, Spine.

[9]  Ganesh Rao,et al.  Surgical management of primary and metastatic sarcoma of the mobile spine. , 2008, Journal of neurosurgery. Spine.

[10]  J. Lin,et al.  The osseous and angiographic features of vertebral chordomas , 1975, Neuroradiology.

[11]  T. Ozaki,et al.  Secondary chondrosarcoma in osteochondromas. Medullary extension in 15 of 45 cases. , 1997, Acta orthopaedica Scandinavica.

[12]  S. Ferrari,et al.  Ewing's sarcoma of the mobile spine. , 2011, European review for medical and pharmacological sciences.

[13]  D. Vanel,et al.  Treatment of nonmetastatic Ewing’s sarcoma family tumors of the spine and sacrum: the experience from a single institution , 2009, European Spine Journal.

[14]  M. Sundaram,et al.  Primary vertebral osteosarcoma: imaging findings. , 2004, Radiology.

[15]  M Beth McCarville,et al.  Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma , 2007, Pediatric blood & cancer.

[16]  Z. L. Gokaslan,et al.  Total en bloc lumbar spondylectomy. Case report. , 2001, Journal of neurosurgery.

[17]  L. Kindblom,et al.  Prognostic factors and outcome of pelvic, sacral, and spinal chondrosarcomas , 2001, Cancer.

[18]  F. Sim,et al.  Osteosarcoma of the spine. , 1986, The Journal of bone and joint surgery. American volume.

[19]  J. Weinstein,et al.  Chordoma of the Mobile Spine: Fifty Years of Experience , 2006, Spine.

[20]  Z. Gokaslan,et al.  Ewing and Osteogenic Sarcoma: Evidence for Multidisciplinary Management , 2009, Spine.

[21]  W. Winkelmann,et al.  Sacral Infiltration in Pelvic Sarcomas: Joint Infiltration Analysis II , 2003, Clinical orthopaedics and related research.

[22]  G. Krol,et al.  Combined treatment of osteosarcoma of the spine , 1988 .

[23]  W. Winkelmann,et al.  Transarticular invasion of iliopelvic sarcomas into the sacrum. Radiological analysis of 47 cases. , 1997, Acta orthopaedica Scandinavica.

[24]  E. Gehan,et al.  Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the second intergroup study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Lorentzon,et al.  The incidence of malignant primary bone tumours in relation to age, sex and site. A study of osteogenic sarcoma, chondrosarcoma and Ewing's sarcoma diagnosed in Sweden from 1958 to 1968. , 1974, The Journal of bone and joint surgery. British volume.

[26]  C. H. Price,et al.  Incidence of bone sarcoma in SW England, 1946-74, in relation to age, sex, tumour site and histology. , 1977, British Journal of Cancer.

[27]  K. Unni,et al.  Chondrosarcoma of the spine. , 1989, The Journal of bone and joint surgery. American volume.

[28]  D. Pritchard,et al.  Primary Ewing's sarcoma of the spine. , 1994, Spine.

[29]  Z. Gokaslan,et al.  Multidisciplinary Management of Primary Tumors of the Vertebral Column , 2009, Current treatment options in oncology.

[30]  I. Spiro.  Sacral Chordoma: 40-Year Experience at a Major Cancer Center , 1999 .

[31]  D. Fairclough,et al.  Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy. , 1991, International journal of radiation oncology, biology, physics.

[32]  Z. L. Gokaslan,et al.  Total en bloc lumbar spondylectomy , 2001 .

[33]  D. Reede,et al.  Computed tomography of spinal chordomas. , 1986, The Journal of computed tomography.

[34]  A. Goldstein,et al.  Chordoma: incidence and survival patterns in the United States, 1973–1995 , 2004, Cancer Causes & Control.

[35]  G. Rosen,et al.  Primary malignant tumors of the spine. , 2009, The Orthopedic clinics of North America.

[36]  G. Fuller,et al.  Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors , 1998, Clinical & Experimental Metastasis.

[37]  G. Krol,et al.  Combined treatment of osteosarcoma of the spine. , 1988, Neurosurgery.

[38]  P. Casali,et al.  Response to imatinib plus sirolimus in advanced chordoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  A. Paulino,et al.  An analysis of primary site control and late effects according to local control modality in non‐metastatic Ewing sarcoma , 2007, Pediatric blood & cancer.

[40]  L. Kindblom,et al.  Prognostic factors in chordoma of the sacrum and mobile spine , 2000, Cancer.

[41]  W. Winkelmann,et al.  Osteosarcoma of the spine , 2002, Cancer.

[42]  G. Gallia,et al.  En bloc resection of primary sacral tumors: classification of surgical approaches and outcome. , 2005, Journal of neurosurgery. Spine.

[43]  A. Abioye,et al.  Primary malignant tumors of bone: incidence in Ibadan, Nigeria. , 1982, Journal of the National Medical Association.